IRVINE, Calif. & LIEGE, Belgium--()--Regulatory News:
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that it received the following notifications, in accordance with the Belgian Act of May 2, 2007 on the disclosure of significant shareholdings in listed companies, as a result of the capital increase announced on June 28 and completed on July 4, 2012:
Shareholdings after actively crossing the transparency threshold:
- Biovest Comm.VA. has informed MDxHealth that its holding in MDxHealth crossed the threshold of 10% of the outstanding shares on July 4, 2012. Biovest Comm.VA. now owns 14.62% of the outstanding shares of MDxHealth.
- Valiance Asset Management has informed MDxHealth that its holding in MDxHealth crossed the threshold of 5% of the outstanding shares on July 4, 2012. Valiance Asset Management now owns 8.22% of the outstanding shares of MDxHealth.
Shareholdings after passively crossing the transparency threshold:
- ING Belgium NV/SA has informed MDxHealth that its holding in MDxHealth fell below the threshold of 10% of the outstanding shares on July 4, 2012. ING Belgium NV/SA now owns 8.42% of the outstanding shares of MDxHealth.
As per July 4, 2012, following the recent capital increase, MDxHealth had € 16 million in cash and cash equivalents ($ 20,2 million).
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information.
For more information visit http://www.mdxhealth.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.